Pressure BioScience’s Pressure-Based Tech Is Ready To Spur Innovation And Growth In A Life Sciences Sector In Flux - Seite 2
Biopharmas Are Betting Big On Cannabis
In 2018, Jazz Pharma's Epidiolex, a seizure medication, became the first and only cannabis-derived prescription drug to receive FDA approval. Since then, more and more clinical trials are underway to develop other therapeutics tapping the plant's medicinal uses, but approval has been painfully slow because complex regulations added so many extra steps and redundancies.
That weedy regulatory landscape changed last year when President Biden signed the Medical Marijuana and Cannabidiol Research Expansion Act into law in December. Drug developers will no longer need to seek separate approval from the Drug Enforcement Agency (DEA). It also enforces shorter DEA registration and review processes and tasks the agency with ensuring that there is an adequate and uninterrupted supply of marijuana for researchers working on new therapeutics.
Earlier that same year, Jazz began construction on a $100 million manufacturing facility that will be dedicated to producing cannabis-based medicines. Meanwhile, the largest cannabinoid manufacturer in the world, Brains Bioceutical Corp signed a landmark CBD supply agreement in April with Brazilian drug manufacturing giant, Prati Donaduzzi.
PBI's UltraShear™ Technology (UST™) platform is tailor-made to produce high-quality CBD nanoemulsions. It does this by breaking down the CBD oil into droplets that are so small, they effectively become water-soluble. That can turn an active ingredient contained in the oil that is typically poorly absorbed by the human body into one that's more easily and more consistently absorbed.
For the pharma companies working on cannabis-derived therapeutics, that improved absorption is key to delivering more precise dosing and developing drugs with more consistent and reliable therapeutic effects. That could be a game changer for medical cannabis research, which has been plagued by promising but inconsistent clinical results due to the low and unpredictable absorption rates of most cannabis-derived compounds.
Featured photo by Julia Koblitz on Unsplash.
Contact:
Lesen Sie auch
Ken Micciche: Director, Business Development
kmicciche@pressurebiosciences.com
SOURCE: Pressure BioSciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/753930/Pressure-BioSciences-Pressure-Based- ...
The Pressure Biosciences Stock at the time of publication of the news with a raise of +13,64 % to 1,00USD on Nasdaq OTC stock exchange (09. Mai 2023, 23:20 Uhr).